NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Tuesday that it has signed a definitive agreement to acquire Crescendo Bioscience for $270 million in cash, though the amount Myriad will pay will be reduced by $25 million for repayment of a loan it previously made to Crescendo.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.